1. Cytogenetic Impact on Lenalidomide Treatment in Relapsed/Refractory Multiple Myeloma: A Real-Life Evaluation
- Author
-
Erica Sechettin, Annalisa Martines, Tamara Berno, Gianpietro Semenzato, Renato Zambello, Chiara Briani, Livio Trentin, Carmela Gurrieri, Francesca Temporin, Laura Bonaldi, Albana Lico, Claudia Battistutta, Claudia Minotto, Francesco Piazza, Monica Cavraro, Antonio Branca, and Elena De March
- Subjects
Adult ,Male ,Oncology ,Cancer Research ,medicine.medical_specialty ,Kaplan-Meier Estimate ,Disease ,Dexamethasone ,Disease-Free Survival ,Young Adult ,Maintenance therapy ,Recurrence ,Internal medicine ,Antineoplastic Combined Chemotherapy Protocols ,medicine ,Humans ,Continous treatment ,Cytogenetic ,Staging system ,Lenalidomide ,Multiple myeloma ,Aged ,Proportional Hazards Models ,Retrospective Studies ,Aged, 80 and over ,Real life evaluation ,Refractory-relapsed multiple myeloma ,business.industry ,Hematology ,Middle Aged ,medicine.disease ,Chromosome Banding ,Thalidomide ,Surgery ,myeloma ,Treatment Outcome ,Life evaluation ,Cohort ,Relapsed refractory ,Female ,Multiple Myeloma ,business ,medicine.drug - Abstract
Introduction In this retrospective real-life study in relapsed/refractory multiple myeloma patients, we analyzed clinical and biologic features distinguishing patients with rapidly progressing disease while receiving lenalidomide therapy from those without progression. Patients and Methods According to time of stopping lenalidomide, patients were subdivided into 3 groups: early stop (ES) (n = 23), when therapy was discontinued within 6 months; intermediate (INT) (n = 23), when therapy was stopped between 7 to 24 months; and long survival (LS) (n = 45), when therapy was maintained for more than 2 years. The median age of the whole cohort was 70 years (range, 42-85 years); 40% had an International Staging System score of 2 or 3. Results High-risk cytogenetic findings, including 1q gain, was reported in 65% ES, 43% INT, and 21% LS. Overall response rate was 63%, with median progression-free survival and overall survival of 33 and 56 months, respectively. Conclusion Although high-risk cytogenetic findings negatively affect progression-free survival and overall survival, 28% of cytogenetic high-risk patients experienced long survival, provided that lenalidomide therapy was not discontinued, thus pointing to the role of maintenance therapy in this subset of patients.
- Published
- 2015